Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06800716 · ClinicalTrials.gov registry record

Impella Reverse Remodeling in End-Stage Heart Failure

A clinical trial of Heart Failure and Cardiomyopathy, sponsored by Columbia University.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT06800716: Recruiting study of Heart Failure and Cardiomyopathy, sponsored by Columbia University.

NCT06800716 is a study of Heart Failure and Cardiomyopathy that is actively recruiting participants, run by Columbia University. The registered enrollment target is 50 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06800716, a study of Heart Failure and Cardiomyopathy, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

This observational study is being done to learn more about heart attack recovery in patients supported with the Impella 5.5 left ventricular assist device (LVAD) as part of their standard of care. There are three stages in this study: screening, treatment and post treatment. There will be two phases of enrollment: First phase will enroll 10 patients; second phase will enroll an additional 40 patients. Approximately 50 participants will take part in the study at Columbia University Irving Medical Center. Participation in this research is expected to last approximately 14 months. This time estimate includes a screening period for about 1- 3 days, treatment period of 40 days and post treatment follow-up period for 1 year. Data will be collected through 1- year after heart transplant. Clinical data (medical history, vital signs, laboratory assessments) from medical records, to perform functional testing, and to obtain blood and discarded heart tissue fromfor the purpose of this research study. Participants will be asked to share their records for echocardiography, right heart catheterization, laboratory data and clinical information. Participants are required to complete an assessment a 6-minute walk, and hand grip strength test.

Primary Outcome

A change in echocardiographic index will be evaluated by measuring a change in LVEF before and after Impella support at minimal pump setting.

Study Locations (1)

New York

  • Columbia University - New York

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-12-04
Est. Completion 2027-11
Columbia University

958 total trials

What NCT06800716 shows while recruiting

NCT06800716 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.

NCT06800716 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06800716 about?

NCT06800716 is a clinical study titled "Impella Reverse Remodeling in End-Stage Heart Failure". This observational study is being done to learn more about heart attack recovery in patients supported with the Impella 5.5 left ventricular assist device (LVAD) as part of their standard of care. There are three stages in this study: screening, treatment and post treatment. There will be two phases...

What is the current status of trial NCT06800716?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-12-04. Estimated completion is 2027-11.

What conditions does trial NCT06800716 study?

This clinical trial studies the following conditions: Heart Failure, Cardiomyopathy.

Who is sponsoring clinical trial NCT06800716?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06800716 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06800716's enrollment target sits among peer trials

50 281st of 397 higher than 106 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06800716, the US trial registry maintained by the National Library of Medicine. NCT06800716 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.